A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.

Original title: “AbiVax falls as safety worries cloud ‘landmark’ immune drug results”

clinical characteristics and outcomes of immune checkpoint inhibitor associated renal toxicities a retrospective pan cancer cohort study

Original title: “Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor Associated Renal Toxicities: A Retrospective Pan-Cancer Cohort Study.”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 4299: Protecting Patient Access to Cancer and Complex Therapies Act”

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Original title: “At ASCO, Merck makes case for a ‘cornerstone’ cancer drug”

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.

Original title: “Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks”

The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.

Original title: “FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs”

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Original title: “Pfizer, Innovent strike $10B cancer drug deal”

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

Original title: “Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent”

The Advanced Therapy Medicinal Products Market Trends are gaining momentum as healthcare systems increasingly adopt gene therapies cell based therapies and tissue engineered products for chronic and rare diseases According to industry estimates the sector is projected to grow from ... Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00012921?utm_source=OpenPR&utm_medium=10812 Rising Adoption of Cell and Gene Therapies Cell and gene therapies are emerging as transformative solutions for diseases that previously had limited treatment options. The increasing prevalence of cancer, hemophilia, muscular dystrophy, and rare genetic disorders is encouraging healthcare providers to adopt innovative therapeutic approaches. Gene therapies are particularly gaining attention for their ability to address the root causes of inherited diseases rather than only managing symptoms. CAR-T therapy has also demonstrated significant clinical success in oncology applications. Press release - The Insight Partners - Advanced Therapy Medicinal Products Market Size to Reach US$ 46.11 Billion by 2034, Growing at 14.79% CAGR During 2026-2034 - published on openPR.com Healthcare providers are increasingly integrating genomic testing, biomarker analysis, and AI-driven diagnostics into treatment planning. This trend is creating significant opportunities for manufacturers developing customized therapeutic solutions. AI-enabled drug discovery platforms are also reducing development timelines and improving clinical trial efficiency. North America currently dominates the global landscape due to strong healthcare infrastructure, high research spending, and supportive regulatory frameworks. The United States remains a major contributor, supported by extensive clinical trial activity and growing demand for innovative therapies.

Original title: “Advanced Therapy Medicinal Products Market Size to Reach US$ 46.11 Billion by 2034, Growing at 14.79% CAGR During 2026-2034”

multiple endocrine adverse reactions and pituitary axis dysfunction induced by pd 1 immunotherapy in an esophageal cancer patient case report

Original title: “Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report.”

Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo's ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.

Original title: “Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues”

worst of both worlds a case series of adenosquamous carcinoma of the esophagus

Original title: “The Worst of Both Worlds: A Case Series of Adenosquamous Carcinoma of the Esophagus.”

characteristic pathological findings of achalasia behind unresectable esophageal cancer with pathological complete response after chemotherapy a case report and literature review

Original title: “Characteristic pathological findings of achalasia behind unresectable esophageal cancer with pathological complete response after chemotherapy: a case report and literature review.”

patients offered genomic testing for rare disease and cancer a real world evaluation of impact and processes of care

Original title: “Patients offered genomic testing for rare disease and cancer: a real-world evaluation of impact and processes of care.”

Ryvu Therapeutics S.A. is progressing its oncology pipeline and funding strategy, drawing attention Ryvu Therapeutics S.A. is progressing its oncology pipeline and funding strategy, drawing attention from biotech-focused investors who follow early-stage cancer drug developers listed on European exchanges but active in global markets. While the firm does not yet have a broadly commercialized product, its long-term growth prospects are tied to clinical milestones and the ability to secure partnerships with larger pharma companies. Funding sources constitute another key driver. Like many development-stage biotech firms, Ryvu Therapeutics S.A. Many US institutional and retail investors access international biotech stocks via depository receipts, cross-listings, or funds that hold European names. As a result, developments at Ryvu Therapeutics S.A., such as progress in clinical trials or new strategic partnerships, can indirectly influence portfolios that include international healthcare exposure. Ryvu Therapeutics S.A. is an oncology-focused biotech company based in Poland, working to advance a portfolio of small-molecule cancer drug candidates through early clinical development. Its business model relies on R&D capabilities, external funding, and the potential for future partnerships, while competitive dynamics in the global oncology field remain intense.

Original title: “Ryvu Therapeutics S.A. stock (PLRVVEL00018): oncology player advances pipeline and funding plans”

Parsortix platform to support minimally invasive analysis across various cancer trials

Original title: “Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies”

A batch of a chemotherapy product made at a Sun facility with a history of quality and compliance issues is being withdrawn from the U.S. market.

Original title: “Sun Pharma recalls cancer drug after finding glass particles in some vials”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.

Original title: “Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment”

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

Original title: “Create Medicines raises $122M to bolster in vivo CAR-T therapies”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 1330: A bill to advance research to achieve medical breakthroughs in brain tumor treatment and improve awareness and adequacy of specialized cancer and brain tumor care.”